Lifesci Capital Initiates Coverage on Tourmaline Bio (NASDAQ:TRML)

Lifesci Capital initiated coverage on shares of Tourmaline Bio (NASDAQ:TRML – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $58.00 price target on the stock. Lifesci Capital’s price objective indicates a potential upside of 362.15% from the company’s […]

Leave a Reply

Your email address will not be published.

Previous post HC Wainwright Reaffirms Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
Next post Head-To-Head Contrast: NPK International (NPKI) versus Its Peers